Cargando…
Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment?
PURPOSE: Acute-on-chronic subdural hematoma (acSDH) describes acute bleeding into a chronic subdural hematoma (SDH), after surgery or second trauma. Because seizures are a well-known complication of SDH, associated with substantial morbidity and mortality, we aimed to analyze the incidence of acute...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001543/ https://www.ncbi.nlm.nih.gov/pubmed/32986132 http://dx.doi.org/10.1007/s00068-020-01508-9 |
_version_ | 1784685696090374144 |
---|---|
author | Won, Sae-Yeon Dubinski, Daniel Freiman, Thomas Seifert, Volker Gessler, Florian Strzelczyk, Adam Konczalla, Juergen |
author_facet | Won, Sae-Yeon Dubinski, Daniel Freiman, Thomas Seifert, Volker Gessler, Florian Strzelczyk, Adam Konczalla, Juergen |
author_sort | Won, Sae-Yeon |
collection | PubMed |
description | PURPOSE: Acute-on-chronic subdural hematoma (acSDH) describes acute bleeding into a chronic subdural hematoma (SDH), after surgery or second trauma. Because seizures are a well-known complication of SDH, associated with substantial morbidity and mortality, we aimed to analyze the incidence of acute symptomatic seizures (ASz), including status epilepticus, and determine the functional outcomes in this specific cohort of patients. METHODS: A retrospective analysis was performed, including patients with acSDH who were admitted to our department between 2010 and 2019. The incidence and timely onset of ASz and status epilepticus were evaluated. Functional outcomes at discharge and at 3–6 month follow-up were analyzed based on the modified Rankin scale. RESULTS: Of 506 patients with chronic SDH, 29 patients (5.7%) were diagnosed with acSDH. The overall incidence of ASz and status epilepticus were 72.4% and 10.3%, respectively. Favorable outcomes were identified in 11 patients (52.4%) in the ASz group compared with 6 patients (75%) in the non-ASz group. The mortality rate was higher in the ASz group compared with that in the control group (29% vs 0%). At follow-up, favorable outcomes were similar to those observed at discharge (52.4% in the ASz group and 71.4% in the control group). The mortality rate was still higher in the ASz group, at 32% compared with 14% for the control group. CONCLUSION: AcSDH has a high risk for ASz, including status epilepticus, and is associated with unfavorable outcomes and high mortality. Thus, prophylactic treatment with antiepileptic drugs should be considered among this specific cohort of patients. |
format | Online Article Text |
id | pubmed-9001543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-90015432022-04-27 Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? Won, Sae-Yeon Dubinski, Daniel Freiman, Thomas Seifert, Volker Gessler, Florian Strzelczyk, Adam Konczalla, Juergen Eur J Trauma Emerg Surg Original Article PURPOSE: Acute-on-chronic subdural hematoma (acSDH) describes acute bleeding into a chronic subdural hematoma (SDH), after surgery or second trauma. Because seizures are a well-known complication of SDH, associated with substantial morbidity and mortality, we aimed to analyze the incidence of acute symptomatic seizures (ASz), including status epilepticus, and determine the functional outcomes in this specific cohort of patients. METHODS: A retrospective analysis was performed, including patients with acSDH who were admitted to our department between 2010 and 2019. The incidence and timely onset of ASz and status epilepticus were evaluated. Functional outcomes at discharge and at 3–6 month follow-up were analyzed based on the modified Rankin scale. RESULTS: Of 506 patients with chronic SDH, 29 patients (5.7%) were diagnosed with acSDH. The overall incidence of ASz and status epilepticus were 72.4% and 10.3%, respectively. Favorable outcomes were identified in 11 patients (52.4%) in the ASz group compared with 6 patients (75%) in the non-ASz group. The mortality rate was higher in the ASz group compared with that in the control group (29% vs 0%). At follow-up, favorable outcomes were similar to those observed at discharge (52.4% in the ASz group and 71.4% in the control group). The mortality rate was still higher in the ASz group, at 32% compared with 14% for the control group. CONCLUSION: AcSDH has a high risk for ASz, including status epilepticus, and is associated with unfavorable outcomes and high mortality. Thus, prophylactic treatment with antiepileptic drugs should be considered among this specific cohort of patients. Springer Berlin Heidelberg 2020-09-28 2022 /pmc/articles/PMC9001543/ /pubmed/32986132 http://dx.doi.org/10.1007/s00068-020-01508-9 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Won, Sae-Yeon Dubinski, Daniel Freiman, Thomas Seifert, Volker Gessler, Florian Strzelczyk, Adam Konczalla, Juergen Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
title | Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
title_full | Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
title_fullStr | Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
title_full_unstemmed | Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
title_short | Acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
title_sort | acute-on-chronic subdural hematoma: a new entity for prophylactic anti-epileptic treatment? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001543/ https://www.ncbi.nlm.nih.gov/pubmed/32986132 http://dx.doi.org/10.1007/s00068-020-01508-9 |
work_keys_str_mv | AT wonsaeyeon acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment AT dubinskidaniel acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment AT freimanthomas acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment AT seifertvolker acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment AT gesslerflorian acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment AT strzelczykadam acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment AT konczallajuergen acuteonchronicsubduralhematomaanewentityforprophylacticantiepileptictreatment |